<p>The present invention discloses a stable crystalline form of Rifaximin characterised by having X-ray powder diffraction pattern as given in figure 1, having a 2? peaks at 7.2 and a broad obtuse peak centred at 2? value 20.0, further characterized by a scanning electron microscope image as given in figure 2, further characterized by a polarising microscope image as given in figure 3 and still further characterized by morphology data as given in figure 4.</p>
